IgGenix sprints to clin­ic with peanut al­ler­gy can­di­date and ad­di­tion­al $40M

A small, Eli Lil­ly-backed biotech has re­ceived $40 mil­lion on its way to the clin­ic with a self-ad­min­is­tered in­jec­tion for peanut al­ler­gies.

IgGenix un­veiled a Se­ries B round on Mon­day to sup­port what CEO Jes­si­ca Gross­man calls a “rev­o­lu­tion­ary” ap­proach to pre­vent­ing both food and non-food al­ler­gies, from dairy to dust to dogs.

When an al­ler­gic re­ac­tion oc­curs, the body pro­duces an el­e­vat­ed amount of al­ler­gen-spe­cif­ic an­ti­bod­ies called im­munoglob­u­lin E, or IgE, trig­ger­ing an al­ler­gic cas­cade that can cause symp­toms from itch­ing to ana­phy­lac­tic shock. IgGenix is look­ing to re-en­gi­neer IgE an­ti­bod­ies, trans­form­ing them in­to IgG an­ti­bod­ies de­signed to al­le­vi­ate the al­ler­gic cas­cade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER